Roivant Sciences Ltd. (ROIV) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 London, 英国. 現任CEO為 Matthew Gline.
ROIV 擁有 IPO日期為 2020-12-08, 908 名全職員工, 在 NASDAQ Global Market, 市值為 $21.03B.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company headquartered in London that researches and develops innovative medicines across multiple therapeutic areas. The company's pipeline includes product candidates targeting oncologic malignancies, rare genetic disorders such as sickle cell disease and hypophosphatasia, and various inflammatory and dermatological conditions including psoriasis, atopic dermatitis, and vitiligo. Additional focus areas encompass autoimmune diseases, ophthalmologic disorders, and infectious diseases. Founded in 2014, Roivant combines drug development expertise with healthcare technology capabilities to address significant unmet medical needs globally.
